The European Commission’s approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November. Other top news included clinical trial updates from Clearside and Adverum.
Here are the top five most-read retina articles of the month:
Europe approves first gene therapy for retinal dystrophy
On Nov. 23, the European Commission approved the first gene therapy for the treatment of inherited retinal disease related to a mutation of the RPE65 gene. Luxturna will be authorized in all 28 EU member states as well as Norway, Iceland and Lichtenstein. Read more.
Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial
Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial. Read more.
First patient dosed in Adverum wet AMD gene therapy trial
The multicenter, open-label OPTIC phase 1 trial is designed to assess the safety and tolerability of a single intravitreal administration of ADVM-022. Eighteen patients will be enrolled in the trial, which will evaluate three doses of the therapy. Read more.
Clearside’s retinal vein occlusion therapy fails to meet phase 3 endpoint
The multicenter, multi-country, randomized, masked phase 3 SAPPHIRE trial compared Xipere — formerly called suprachoroidal CLS-TA, a proprietary suspension of triamcinolone acetonide — used together with intravitreal Eylea (aflibercept, Regeneron) to Eylea monotherapy. Read more.
Ophthotech acquires Versant Ventures-backed Inception 4
Ophthotech Corp. has acquired Inception 4 Inc. and its small molecule inhibitors of HtrA1, which are under development for the treatment of a range of retinal diseases. Read more.